Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
BioHarvest Sciences Inc. Common Stock
BHST
NASDAQ·Basic Materials·Agricultural Inputs·Mkt cap $50.4M
$2.87
▼ -1.37%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$2.75 - $12.80
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 57.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary botanical synthesis platform enabling cell-based plant ingredient production
- Clinically validated products with established efficacy data
- Sustainable, controlled-environment cultivation reducing agricultural dependencies
- Dual-revenue model combining consumer products with B2B CDMO services
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Expanding global demand for plant-based and natural health ingredients
Value
Deep value opportunity - significant discount to Fertilizers & Agricultural Chemicals peers
Momentum
Falling
-32.0% over 3m
Quality
Strong
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying BHST right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 10, 2026
MAY 14, 2026
Reported EPS of -$0.11 vs -$0.13 consensus (+15.4% surprise). Revenue of $8.5M vs $8.5M expected (+0.1%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+15.4%
Next: Aug 10, 2026
Revenue trend · last 8Q
—
—
—
+47%
+41%
+39%
+25%
+8%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$6.0M
$6.5M
$7.3M
$7.9M
$8.5M
$9.1M
$9.1M
$8.5M
Margins · last 8Q
Gross
—
Operating
—
Profit
-31.1%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
No analyst coverage on file for this stock yet.